Sugi Predict

Sugi Predict / Compounds / SCHEMBL1137692

SCHEMBL1137692

SCHEMBL1137692

CC(C)(C)OC(=O)Nc1nnc[nH]1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ LCK P06239 1/20 0.37
▸ CYP17A1 P05093 2/20 0.37
▸ ATR Q13535 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PSMB8 P28062 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SYK P43405 1/20 0.34
▸ APLNR P35414 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ BRD9 Q9H8M2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20078909 0.77 KMT2A (0.50) RAB9ANPC1SMN1; SMN2
SCHEMBL28976991 0.74 CA1 (0.42) CA1CA2LCKCYP17A1ATR
SCHEMBL2698206 0.73 ATR (0.43) LCKCYP17A1ATRRAB9ANPC1
SCHEMBL13411799 0.72 RAB9A (0.35) L3MBTL1RAB9ANPC1SMN1; SMN2
SCHEMBL13446569 0.72 ALDH1A1 (0.39) CYP17A1SMN1; SMN2
SCHEMBL4358474 0.71 CA1 (0.43) CA1CA2LCKCYP17A1ATR
SCHEMBL9109986 0.70 CYP17A1 (0.41) CYP17A1ATRL3MBTL1RAB9ASMN1; SMN2
SCHEMBL18048108 0.70 LCK (0.37) CA1CA2LCKCYP17A1ATR
SCHEMBL13411769 0.70 BCHE (0.38) RAB9ABCHE
SCHEMBL17950141 0.69 GAA (0.47) L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 — — US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 — — US disclosed
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 — — US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 — — US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 — — US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, MPO, GCK CA1 1687/4885CA2 1290/4885LCK 627/4885
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 CA1 2179/4885CA2 846/4885LCK 776/4885
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 CA1 2250/4885CA2 766/4885LCK 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.